Perry A. Karsen

Perry A. Karsen is a declared insider at 6 companies; the most frequent names are Celgene Corp /DE/, Intellia Therapeutics, Inc. and Navidea Biopharmaceuticals, Inc. Between 13 May 2013 and 3 May 2023, the trades on record add up to 58 filings.

Both buying and selling appear: 2 purchases worth €105k, against 11 sales worth €30.6M. Sales outweigh purchases by €30.5M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 16 share grants and 25 option exercises.

The newest entry dates from 4 May 2023: a transaction, in Jounce Therapeutics, Inc. The most recent open-market purchase was published on 7 June 2017, 3,425 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.